TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T67162	Dopamine D2 receptor	D0J5RN	Armodafinil	Approved	9690109	C15H15NO2S	273.4	C1=CC=C(C=C1)C(C2=CC=CC=C2)[S@](=O)CC(=O)N	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	D0Z1WA	Procaterol	Approved	4916	C16H22N2O3	290.36	CCC(C(C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C	Ki = 86000 nM	Poor binder
T67162	Dopamine D2 receptor	D0N1HW	L-745,870	Phase 2	5311200	C18H19ClN4	326.8	C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)Cl	Ki = 53703.18 nM	Poor binder
T67162	Dopamine D2 receptor	D03TNA	ABT-724	Discontinued in Phase 2	5025739	C17H19N5	293.4	C1CN(CCN1CC2=NC3=CC=CC=C3N2)C4=CC=CC=N4	Ki = 51000 nM	Poor binder
T67162	Dopamine D2 receptor	D0BN4Y	Ebalzotan	Discontinued in Phase 1	9797080	C19H30N2O2	318.5	CCCN([C@@H]1CC2=C(C=CC=C2OC1)C(=O)NC(C)C)C(C)C	Ki ~ 50000 nM	Poor binder
T67162	Dopamine D2 receptor	D0Y6GJ	ZM-241385	Terminated	176407	C16H15N7O2	337.34	C1=COC(=C1)C2=NN3C(=NC(=NC3=N2)NCCC4=CC=C(C=C4)O)N	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	B0I3AR	4-[4-(4-Chlorophenyl)piperazine-1-ylmethyl]pyrazolo[1,5-a]pyridine-3-methanol	Investigative	11078813	C19H21ClN4O	356.8	C1CN(CCN1CC2=CC=CN3C2=C(C=N3)CO)C4=CC=C(C=C4)Cl	Ki = 53000 nM	Poor binder
T67162	Dopamine D2 receptor	B0OSR9	7-(2-Methoxyphenyl)-2-[3-[(4-methyl-5-phenyl-1,2,4-triazol-3-yl)sulfanyl]propyl]-2,7-diazaspiro[3.4]octane	Investigative	137641643	C25H31N5OS	449.6	CN1C(=NN=C1SCCCN2CC3(C2)CCN(C3)C4=CC=CC=C4OC)C5=CC=CC=C5	Ki = 60152 nM	Poor binder
T67162	Dopamine D2 receptor	B0WP8D	4-(2-Piperazin-1-ylethyl)-1,3-dihydroindol-2-one	Investigative	117365679	C14H19N3O	245.32	C1CN(CCN1)CCC2=C3CC(=O)NC3=CC=C2	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	B1HYO7	(11R)-5-Methyl-6,11-dioxo-N-(2-thiophen-2-ylethyl)benzo[b][1,4]benzothiazepine-3-carboxamide	Investigative	57383408	C21H18N2O3S2	410.5	CN1C2=C(C=CC(=C2)C(=O)NCCC3=CC=CS3)[S@](=O)C4=CC=CC=C4C1=O	Ki ~ 50000 nM	Poor binder
T67162	Dopamine D2 receptor	B1KS0X	4-[2-(1,4-Diazepan-4-ium-1-yl)ethyl]-1,3-dihydroindol-2-one;2,2,2-trifluoroacetate	Investigative	118726019; 145948564	C17H22F3N3O3	373.4	C1C[NH2+]CCN(C1)CCC2=C3CC(=O)NC3=CC=C2.C(=O)(C(F)(F)F)[O-]	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	B1NMB8	2-[[(2R)-2-Phenethylmorpholino]methyl]-1H-benzoimidazole	Investigative	60149678	C20H23N3O	321.4	C1CO[C@@H](CN1CC2=NC3=CC=CC=C3N2)CCC4=CC=CC=C4	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	B2FH0S	Tert-butyl 4-[2-(2-oxo-1,3-dihydroindol-4-yl)ethyl]piperazine-1-carboxylate	Investigative	118726017	C19H27N3O3	345.4	CC(C)(C)OC(=O)N1CCN(CC1)CCC2=C3CC(=O)NC3=CC=C2	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	B2K7JI	N-[4-[4-(4-Chlorophenyl)piperazin-1-yl]butyl]-5-phenyl-1,2,4-oxadiazol-3-amine;hydrochloride	Investigative	127038078	C22H27Cl2N5O	448.4	C1CN(CCN1CCCCNC2=NOC(=N2)C3=CC=CC=C3)C4=CC=C(C=C4)Cl.Cl	Ki = 79630 nM	Poor binder
T67162	Dopamine D2 receptor	B2WF6H	((R)-7-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amine	Investigative	15651970	C14H21NO	219.32	CCCN[C@@H]1CCC2=C(C1)C=C(C=C2)OC	Ki = 58882 nM	Poor binder
T67162	Dopamine D2 receptor	B3FG4C	(2S,3S,4S,5R,6R)-2-(Fluoromethyl)-6-[4-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]triazol-1-yl]oxane-3,4,5-triol	Investigative	72545010	C20H28FN5O5	437.5	COC1=CC=CC=C1N2CCN(CC2)CC3=CN(N=N3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CF)O)O)O	Ki = 51000 nM	Poor binder
T67162	Dopamine D2 receptor	B3V5IK	5-Propylamino-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridine-3-carboxylic acid methyl ester	Investigative	11630058	C12H19N3O2	237.3	CCCNC1CCN2C(=C(C=N2)C(=O)OC)C1	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	B4G1WA	3-[4-(4-Chlorophenyl)piperazinomethyl]-4-(hydroxymethyl)pyrazolo[1,5-a]pyridine	Investigative	44372312	C19H21ClN4O	356.8	C1CN(CCN1CC2=C3C(=CC=CN3N=C2)CO)C4=CC=C(C=C4)Cl	Ki = 56000 nM	Poor binder
T67162	Dopamine D2 receptor	B4QRD1	5-N-[2-[4-[(4-Chloro-6-morpholin-4-yl-1,3,5-triazin-2-yl)oxy]phenyl]ethyl]-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine	Investigative	118726005	C23H22ClN11O3	535.9	C1COCCN1C2=NC(=NC(=N2)Cl)OC3=CC=C(C=C3)CCNC4=NC5=NC(=NN5C(=N4)N)C6=CC=CO6	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	B5F3RV	3-(2,3,4,9-Tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenol	Investigative	198914	C17H16N2O	264.32	C1CNC(C2=C1C3=CC=CC=C3N2)C4=CC(=CC=C4)O	Ki = 88000 nM	Poor binder
T67162	Dopamine D2 receptor	B5IRY7	Methyl 12-[4-[4-[2-[[7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenoxy]butanoylamino]dodecanoate	Investigative	118726004	C33H46N8O5	634.8	COC(=O)CCCCCCCCCCCNC(=O)CCCOC1=CC=C(C=C1)CCNC2=NC3=NC(=NN3C(=N2)N)C4=CC=CO4	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	B5MGK3	6-Methoxy-1-(1-methyl-4-nitro-1H-pyrrol-2-yl)-4,9-dihydro-3H-pyrido[3,4-b]indole	Investigative	44439389	C17H16N4O3	324.33	CN1C=C(C=C1C2=NCCC3=C2NC4=C3C=C(C=C4)OC)[N+](=O)[O-]	Ki = 200000 nM	Poor binder
T67162	Dopamine D2 receptor	B5QZ6U	4-[2-[[7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-propylamino]ethyl]-1,3-dihydroindol-2-one	Investigative	118726008	C21H22N8O2	418.5	CCCN(CCC1=C2CC(=O)NC2=CC=C1)C3=NC4=NC(=NN4C(=N3)N)C5=CC=CO5	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	B67VFR	3-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}propyl-(3,4-dihydroisoquinoline)	Investigative	25156416	C27H31NO2	401.5	COC1=CC=CC(=C1)CCC2=CC=CC=C2OCCCN3CCC4=CC=CC=C4C3	Ki = 114000 nM	Poor binder
T67162	Dopamine D2 receptor	B67YHI	6-Chloro-3-(4-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)quinoline	Investigative	24894134	C22H17Cl2FN4O	443.3	C1CN(CCC1C2=NC(=NO2)C3=C(C=C(C=C3)F)Cl)C4=CN=C5C=CC(=CC5=C4)Cl	IC50 ~ 50000 nM	Poor binder
T67162	Dopamine D2 receptor	B6Y7FR	(E)-N-((6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methylene)-3,4a,9,9a-tetrahydro-2H-indeno[1,2-b][1,4]dithiin-6-amine	Investigative	44439408	C23H26N2O2S2	426.6	COC1=C(C=C2CN(CCC2=C1)C=NC3=CC4=C(CC5C4SCCS5)C=C3)OC	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	B7OMK0	4-(1H-Benzimidazol-2-ylmethyl)-2-(2-phenylethyl)morpholine	Investigative	19964406	C20H23N3O	321.4	C1COC(CN1CC2=NC3=CC=CC=C3N2)CCC4=CC=CC=C4	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	B7X8IQ	3-(4-Allylmorpholin-2-yl)phenol	Investigative	44443903	C13H17NO2	219.28	C=CCN1CCOC(C1)C2=CC(=CC=C2)O	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	B8VTK7	1-(4-Fluorophenyl)-6-[3-[(4-methyl-5-phenyl-1,2,4-triazol-3-yl)sulfanyl]propyl]-1,6-diazaspiro[3.3]heptane	Investigative	137662048	C23H26FN5S	423.6	CN1C(=NN=C1SCCCN2CC3(C2)CCN3C4=CC=C(C=C4)F)C5=CC=CC=C5	Ki ~ 109574 nM	Poor binder
T67162	Dopamine D2 receptor	B97EOI	(E)-Tert-butyl 6-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyleneamino)indoline-1-carboxylate	Investigative	44439397	C25H31N3O4	437.5	CC(C)(C)OC(=O)N1CCC2=C1C=C(C=C2)N=CN3CCC4=CC(=C(C=C4C3)OC)OC	Ki = 54000 nM	Poor binder
T67162	Dopamine D2 receptor	B9PM5U	N-(Propan-2-yl)-1H-indole-2-carboxamide	Investigative	13680883	C12H14N2O	202.25	CC(C)NC(=O)C1=CC2=CC=CC=C2N1	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	B9SRJ5	3-(4-Methoxyphenyl)-9-[3-[(4-methyl-5-phenyl-1,2,4-triazol-3-yl)sulfanyl]propyl]-3,9-diazaspiro[5.5]undecane	Investigative	137659335	C28H37N5OS	491.7	CN1C(=NN=C1SCCCN2CCC3(CC2)CCN(CC3)C4=CC=C(C=C4)OC)C5=CC=CC=C5	Ki = 104847 nM	Poor binder
T67162	Dopamine D2 receptor	BA79RW	(R)-3-[Isopropyl(propyl)amino]-3,4-dihydro-2H-1-benzopyran-5-carboxamide	Investigative	10084845	C16H24N2O2	276.37	CCCN([C@@H]1CC2=C(C=CC=C2OC1)C(=O)N)C(C)C	Ki ~ 50000 nM	Poor binder
T67162	Dopamine D2 receptor	BAH03J	2-[4-(4-Fluorophenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyrazine	Investigative	11659604	C17H18FN5	311.36	C1CN(CCN1CC2=CN3C=CN=CC3=N2)C4=CC=C(C=C4)F	Ki = 64000 nM	Poor binder
T67162	Dopamine D2 receptor	BAH37R	(E)-N-((6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methylene)-2,3,4a,5,6,10b-hexahydronaphtho[1,2-b][1,4]dithiin-9-amine	Investigative	44439405	C24H28N2O2S2	440.6	COC1=C(C=C2CN(CCC2=C1)C=NC3=CC4=C(CCC5C4SCCS5)C=C3)OC	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BB02JO	(E)-N-Benzyl-N''-(3-hydroxy-2,3-dihydro-1H-inden-5-yl)-N-methylformamidine	Investigative	44439410	C18H20N2O	280.4	CN(CC1=CC=CC=C1)C=NC2=CC3=C(CCC3O)C=C2	Ki = 59000 nM	Poor binder
T67162	Dopamine D2 receptor	BB60OA	4-[2-[4-[[7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]piperidin-1-yl]ethyl]-1,3-dihydroindol-2-one	Investigative	118726016	C23H25N9O2	459.5	C1CN(CCC1NC2=NC3=NC(=NN3C(=N2)N)C4=CC=CO4)CCC5=C6CC(=O)NC6=CC=C5	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BBR4A3	4-[4-(Pyrazolo[1,5-a]pyridin-3-ylmethyl)piperazin-1-yl]phenol	Investigative	24824066	C18H20N4O	308.4	C1CN(CCN1CC2=C3C=CC=CN3N=C2)C4=CC=C(C=C4)O	Ki = 87000 nM	Poor binder
T67162	Dopamine D2 receptor	BC2SZ6	(2S)-4-(1H-Benzimidazol-2-ylmethyl)-2-(2-phenylethyl)morpholine	Investigative	92640710	C20H23N3O	321.4	C1CO[C@H](CN1CC2=NC3=CC=CC=C3N2)CCC4=CC=CC=C4	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BD3BJ5	[1-[2-(2-Oxo-1,3-dihydroindol-4-yl)ethyl]piperidin-4-yl] N-tert-butylcarbamate	Investigative	118726014	C20H29N3O3	359.5	CC(C)(C)NC(=O)OC1CCN(CC1)CCC2=C3CC(=O)NC3=CC=C2	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BD7W4Y	Pyrazolo[1,5-a]pyridine,2-[[4-[4-(2-fluoroethoxy)phenyl]-1-piperazinyl]methyl]-	Investigative	24824063	C20H23FN4O	354.4	C1CN(CCN1CC2=NN3C=CC=CC3=C2)C4=CC=C(C=C4)OCCF	Ki = 50000 nM	Poor binder
T67162	Dopamine D2 receptor	BDEI80	3-{[4-(4-Chlorophenyl)piperazin-1-yl]methyl}-2,5,7-trimethylimidazo[1,2-c]pyrimidine	Investigative	45271691	C20H24ClN5	369.9	CC1=CC2=NC(=C(N2C(=N1)C)CN3CCN(CC3)C4=CC=C(C=C4)Cl)C	Ki = 57000 nM	Poor binder
T67162	Dopamine D2 receptor	BFG51U	[(1S,2R,5S,6S,7S)-3-Benzyl-2-methyl-7-pyrrolidin-1-yl-3-azabicyclo[3.2.0]heptan-6-yl]methanol	Investigative	70686494	C19H28N2O	300.4	C[C@@H]1[C@@H]2[C@H](CN1CC3=CC=CC=C3)[C@@H]([C@H]2N4CCCC4)CO	Ki = 66000 nM	Poor binder
T67162	Dopamine D2 receptor	BFP4Q1	4-[2-[4-[7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one	Investigative	118726021	C22H23N9O2	445.5	C1CN(CCN1CCC2=C3CC(=O)NC3=CC=C2)C4=NC5=NC(=NN5C(=N4)N)C6=CC=CO6	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BFSU72	9-[3-[(4-Methyl-5-phenyl-1,2,4-triazol-3-yl)sulfanyl]propyl]-3-pyridin-2-yl-3,9-diazaspiro[5.5]undecane	Investigative	137652312	C26H34N6S	462.7	CN1C(=NN=C1SCCCN2CCC3(CC2)CCN(CC3)C4=CC=CC=N4)C5=CC=CC=C5	Ki = 83671 nM	Poor binder
T67162	Dopamine D2 receptor	BH5T1K	1,2,3,4-Tetrahydroisoquinoline-6-carbonitrile	Investigative	10241065	C10H10N2	158.2	C1CNCC2=C1C=C(C=C2)C#N	Ki = 53800 nM	Poor binder
T67162	Dopamine D2 receptor	BHP52J	Dopamine hydrochloride	Investigative	65340	C8H12ClNO2	189.64	C1=CC(=C(C=C1CCN)O)O.Cl	IC50 = 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BI5W4E	1-(1-Benzyl-4-piperidinyl)-1H-pyrrole-3-carbaldehyde	Investigative	15508242	C17H20N2O	268.35	C1CN(CCC1N2C=CC(=C2)C=O)CC3=CC=CC=C3	Ki = 65000 nM	Poor binder
T67162	Dopamine D2 receptor	BI6Y8K	(S)-N-Isopropyl-3-[isopropyl(propyl)amino]-3,4-dihydro-2H-1-benzopyran-5-carboxamide	Investigative	10639290	C19H30N2O2	318.5	CCCN([C@H]1CC2=C(C=CC=C2OC1)C(=O)NC(C)C)C(C)C	Ki ~ 50000 nM	Poor binder
T67162	Dopamine D2 receptor	BI95PL	(4-Bromothiophen-2-yl)(4-fluoro-4-(((5-methylpyridin-2-yl)methylamino)methyl)piperidin-1-yl)methanone	Investigative	42605994	C18H21BrFN3OS	426.3	CC1=CN=C(C=C1)CNCC2(CCN(CC2)C(=O)C3=CC(=CS3)Br)F	Ki = 73000 nM	Poor binder
T67162	Dopamine D2 receptor	BJ6A8W	1-(2-Methoxyphenyl)-6-[3-[(4-methyl-5-phenyl-1,2,4-triazol-3-yl)sulfanyl]propyl]-1,6-diazaspiro[3.3]heptane	Investigative	137649193	C24H29N5OS	435.6	CN1C(=NN=C1SCCCN2CC3(C2)CCN3C4=CC=CC=C4OC)C5=CC=CC=C5	Ki = 114945 nM	Poor binder
T67162	Dopamine D2 receptor	BJYS45	2-[5-(4-Phenylpiperazinomethyl)-1H-pyrrole-2-ylmethylene]malononitrile	Investigative	15467369	C19H19N5	317.4	C1CN(CCN1CC2=CC=C(N2)C=C(C#N)C#N)C3=CC=CC=C3	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BKG63Q	Benzo[b]thiophen-3-yl(4-fluoro-4-(((5-methylpyridin-2-yl)methylamino)methyl)piperidin-1-yl)methanone	Investigative	42606339	C22H24FN3OS	397.5	CC1=CN=C(C=C1)CNCC2(CCN(CC2)C(=O)C3=CSC4=CC=CC=C43)F	Ki = 54000 nM	Poor binder
T67162	Dopamine D2 receptor	BLQN95	2-{5-[4-(4-Chloro-phenyl)-piperazin-1-ylmethyl]-1H-pyrrol-2-ylmethylene}-malononitrile	Investigative	15467370	C19H18ClN5	351.8	C1CN(CCN1CC2=CC=C(N2)C=C(C#N)C#N)C3=CC=C(C=C3)Cl	Ki = 59000 nM	Poor binder
T67162	Dopamine D2 receptor	BM38YN	Dipropyl-(R)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridin-5-yl-amine	Investigative	11708363	C13H23N3	221.34	CCCN(CCC)[C@@H]1CCN2C(=CC=N2)C1	Ki = 53000 nM	Poor binder
T67162	Dopamine D2 receptor	BM68LY	2-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}ethyl-4-(N-methyl)piperazine	Investigative	25157260	C22H30N2O2	354.5	CN1CCN(CC1)CCOC2=CC=CC=C2CCC3=CC(=CC=C3)OC	Ki = 178000 nM	Poor binder
T67162	Dopamine D2 receptor	BN4A1L	Tert-butyl 4-[2-(2-oxo-1,3-dihydroindol-4-yl)ethyl]-1,4-diazepane-1-carboxylate	Investigative	118726018	C20H29N3O3	359.5	CC(C)(C)OC(=O)N1CCCN(CC1)CCC2=C3CC(=O)NC3=CC=C2	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BP4AJ5	3-(4-Fluorophenyl)-9-methyl-1-oxa-9-azaspiro[5.5]undec-2-en-4-one;hydrochloride	Investigative	45260679	C16H19ClFNO2	311.78	CN1CCC2(CC1)CC(=O)C(=CO2)C3=CC=C(C=C3)F.Cl	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BPU93B	4-[2-(4-Aminopiperidin-1-yl)ethyl]-1,3-dihydroindol-2-one	Investigative	118726015	C15H21N3O	259.35	C1CN(CCC1N)CCC2=C3CC(=O)NC3=CC=C2	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BQ68TB	3-[9-[3-[(4-Methyl-5-phenyl-1,2,4-triazol-3-yl)sulfanyl]propyl]-3,9-diazaspiro[5.5]undecan-3-yl]benzonitrile	Investigative	137650900	C28H34N6S	486.7	CN1C(=NN=C1SCCCN2CCC3(CC2)CCN(CC3)C4=CC=CC(=C4)C#N)C5=CC=CC=C5	Ki = 57101 nM	Poor binder
T67162	Dopamine D2 receptor	BQP26D	7-[4-(4-Chlorophenyl)piperazine-1-ylmethyl]pyrazolo[1,5-a]pyridine	Investigative	11077918	C18H19ClN4	326.8	C1CN(CCN1CC2=CC=CC3=CC=NN32)C4=CC=C(C=C4)Cl	Ki = 67000 nM	Poor binder
T67162	Dopamine D2 receptor	BS6RU4	(-)-Govadine	Investigative	56968583	C19H22ClNO4	363.8	COC1=C(C=C2[C@@H]3CC4=CC(=C(C=C4CN3CCC2=C1)O)OC)O.Cl	EC50 = 56000 nM	Poor binder
T67162	Dopamine D2 receptor	BT7BW6	3-{[4-(2-Methoxyphenyl)piperazin-1-yl]methyl}-2,7-dimethylimidazo[1,2-c]pyrimidine	Investigative	45267409	C20H25N5O	351.4	CC1=CC2=NC(=C(N2C=N1)CN3CCN(CC3)C4=CC=CC=C4OC)C	Ki = 53000 nM	Poor binder
T67162	Dopamine D2 receptor	BVJ5F4	2-[3-[4-(4-Methoxyphenyl)piperazin-1-yl]propyl]-4,5-dihydro-3H-2-benzazepin-1-one	Investigative	44582492	C24H31N3O2	393.5	COC1=CC=C(C=C1)N2CCN(CC2)CCCN3CCCC4=CC=CC=C4C3=O	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BVL9K2	4-[2-[4-[7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-1,4-diazepan-1-ium-1-yl]ethyl]-1,3-dihydroindol-2-one;2,2,2-trifluoroacetate	Investigative	118726022; 145948565	C25H26F3N9O4	573.5	C1C[NH+](CCN(C1)C2=NC3=NC(=NN3C(=N2)N)C4=CC=CO4)CCC5=C6CC(=O)NC6=CC=C5.C(=O)(C(F)(F)F)[O-]	EC50 ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BWI62X	9-Methyl-3-phenyl-1-oxa-9-azaspiro[5.5]undec-2-en-4-one;hydrochloride	Investigative	45264511	C16H20ClNO2	293.79	CN1CCC2(CC1)CC(=O)C(=CO2)C3=CC=CC=C3.Cl	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BXQ53G	4{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}butyl-4-(2''-methoxyphenyl)piperazine	Investigative	25158435	C30H38N2O3	474.6	COC1=CC=CC(=C1)CCC2=CC=CC=C2OCCCCN3CCN(CC3)C4=CC=CC=C4OC	Ki = 67000 nM	Poor binder
T67162	Dopamine D2 receptor	BY9IU1	2-[4-(4-Fluorophenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyrimidine	Investigative	11652518	C17H18FN5	311.36	C1CN(CCN1CC2=CN3C=CC=NC3=N2)C4=CC=C(C=C4)F	Ki = 55000 nM	Poor binder
T67162	Dopamine D2 receptor	BYL57H	2-Methyl-3-[4-(4-chlorophenyl)piperazinomethyl]-7-cyanopyrazolo[1,5-a]pyridine	Investigative	10361512	C20H20ClN5	365.9	CC1=NN2C(=C1CN3CCN(CC3)C4=CC=C(C=C4)Cl)C=CC=C2C#N	Ki = 58000 nM	Poor binder
T67162	Dopamine D2 receptor	BZ9UC6	N-(Cyclopropylmethyl)-1H-indole-2-carboxamide	Investigative	23025506	C13H14N2O	214.26	C1CC1CNC(=O)C2=CC3=CC=CC=C3N2	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	BZPK29	3-[[4-[4-(2-Fluoroethoxy)phenyl]piperazin-1-yl]methyl]pyrazolo[1,5-a]pyridine	Investigative	10247561	C20H23FN4O	354.4	C1CN(CCN1CC2=C3C=CC=CN3N=C2)C4=CC=C(C=C4)OCCF	Ki = 66000 nM	Poor binder
T67162	Dopamine D2 receptor	D04CPW	N-(4-Propylaminobutyl)-4-biphenylcarboxamide	Investigative	25139331	C20H26N2O	310.4	CCCNCCCCNC(=O)C1=CC=C(C=C1)C2=CC=CC=C2	Ki ~ 100000 nM	Poor binder
T67162	Dopamine D2 receptor	D0C5RZ	tyramine	Investigative	5610	C8H11NO	137.18	C1=CC(=CC=C1CCN)O	Ki = 160000 nM	Poor binder
T67162	Dopamine D2 receptor	D0N6OL	ADS-103253	Investigative	11452268	C21H21ClN4O2	396.9	CC1=C2C=C(C=CC2=NC(=N1)N3CCCC3)NC(=O)COC4=CC=C(C=C4)Cl	IC50 ~ 100000 nM	Poor binder